Russia has announced the development of a personalized mRNA cancer vaccine named EnteroMix, which is set to begin patient treatment in October 2025. The vaccine leverages technology akin to that used in COVID-19 mRNA vaccines but employs AI-driven algorithms to generate individualized mRNA blueprints based on patients’ genetic data, drastically reducing development time from months to hours.
The Russian Federal Medical and Biological Agency (FMBA) confirmed the vaccine’s readiness for clinical use, citing 100% efficacy in early trials. Reports indicate it has successfully shrunk and destroyed tumors with no major side effects, targeting lung, breast, colorectal, pancreatic, and chemo-resistant cancers. The FMBA’s head, Veronica Skvortsova, stated the vaccine passed preclinical trials, demonstrating safety and significant tumor reduction while being suitable for repeated use.
Developed by the Ministry of Health’s National Medical Research Radiology Centre in collaboration with the Engelhardt Institute of Molecular Biology, EnteroMix is tailored to each patient’s RNA, offering a fully personalized therapy. Initial focus areas include colorectal cancer, with additional versions under development for glioblastoma and specific melanoma forms.
The vaccine’s creation follows a three-step process: AI-generated genetic blueprints, mRNA synthesis at the Gamaleya Center, and immune response activation. Preclinical trials reported reduced tumor growth and metastasis risks, with developers emphasizing adaptability to over 300 known cancer types. Russia plans to launch human trials and offer the vaccine free of charge as part of its national healthcare strategy.
